Pdb70 - Economic Evaluation of the Use of Recombinant Human Epidermal Growth Factor (Heberprot-P®) as an Adjuvant of Conventional Therapy for the Treatment of Diabetic Foot Ulcer

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.775
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Topical Recombinant Human Epidermal Growth Factor for Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Clinical Trials

Annals of Vascular Surgery
MedicineSurgeryCardiovascular MedicineCardiology
2020English

Analysis of the Clinical Application of Epidermal Growth Factor ("Heberprot-P") and Bioplastic Material ("Collost") in Treatment of Skin and Soft Tissues Defects in Patients With Diabetic Foot Syndrome

Khirurgiya
MedicineSurgery
2016English

The Use of Recombinant Epidermal Growth Factor in Primary Health Assistance

Hospice and Palliative Medicine International Journal
2018English

Epidermal Growth Factor Versus Conventional Wound Dressings in Treatment of Diabetic Ulcers- A Comparative Study

IOSR Journal of Dental and Medical Sciences
2017English

Physical Therapy as an Adjuvant Treatment for the Prevention and Treatment of Cancer

Klinicka Onkologie
Oncology
2020English

Angioplasty as an Adjuvant Therapy for the Treatment of Acute Ischemic Stroke

Canadian Journal of Neurological Sciences
MedicineNeurology
2011English

Case Report on the Use of a Honey on Diabetic Foot Ulcer Patients

International Journal of Indonesian National Nurses Association (IJINNA)
2018English

Maggot Debridement Therapy for Diabetic Foot Ulcer: A Case Report

Journal of Critical Care Nursing
2017English

Negative Pressure Therapy in the Surgical Treatment of Diabetic Foot

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy